Abstract 453P
Background
Obesity is a risk factor for the development of new cases of breast cancer and also affects survival in women who have already been diagnosed with breast cancer, but in Asian women, these findings is not evident. We aimed to investigate the correlation between the body mass index (BMI) and overall survival of patients with a breast cancer.
Methods
We conducted a retrospective observational study from a single institute from January 2014 to December 2018. Among all 412 patients diagnosed and treated with breast cancer, we categorized them as three groups (low weight: BMI < 18kg/m2, normal: BMI < 25kg/m2, obesity: BMI ≥25kg/m2) and investigated overall survival according to menopausal status and adjuvant endocrine therapy. We used a kaplan-meier analysis with log-rank test.
Results
Total 412 patients were enrolled. Mean duration of follow up was 33.3 months. Obesity, normal BMI and low BMI was 120(29.1%), 202(49.0%), and 40 (9.7%) patients, respectively. BMI was correlated with age, patients with obesity was 16% (28/174) of women with less than 50 years, but 38.6% (92/238) of women with more than 50 years. Overall survival was not significantly different among groups (Obesity group: 95%, Normal group: 95.5%, low BMI: 97.5%, p = 0.77, χ2=1.1). Women without adjuvant hormone therapy show lower overall survival, but it is not significant (Obesity group: 87.7%, Normal group: 94.4%, low BMI: 90%, p = 0.89, χ2=0.62). In women with more than 50 years, low BMI was better than normal to obese women (p = 0.89, χ2=0.6).
Conclusions
Obesity is not major risk factor of overall survival in Korea, but in hormone receptor negative breast cancers, it correlated with early onset death or recurrence. Not only further studies need to lighten the relationship between obesity and long-term survival, but also intervention to reduce BMI needs to know its effects on breast cancer survival in Korea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract